Antisense development has required diligent efforts by many labs to allow it to progress. Improved methods have helped to transgress many barriers, resulting in a vibrant technology geared towards generating new human therapuetics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zamecnik, P.C. & Stephenson, M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. natn. Acad. Sci. U.S.A. 75, 280–284 (1978).
Stein, C.A. & Krieg, A.M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67–69 (1994).
Wagner, R.W. Gene inhibition using anti-sense oligodeoxynucleotides. Nature 372, 333–335 (1994).
Wagner, R.W. et al. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260, 1510–1513 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, R. The state of the art in antisense research. Nat Med 1, 1116–1118 (1995). https://doi.org/10.1038/nm1195-1116
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1195-1116
